our Premium Content: News alerts, weekly reports and conference planners

GENE:

CCL11 (C-C Motif Chemokine Ligand 11)

News alerts, weekly reports and conference planners

17d

The Causal Role of Circulating Inflammatory Cytokines in Brain Tumors: Insights from Genetic Epidemiology. (PubMed, Immunol Invest)

For astrocytoma, risk factors included Eotaxin, Macrophage colony-stimulating factor 1, and Interleukin-8; protective factors were T-cell surface glycoprotein CD5 and Tumor necrosis factor ligand superfamily member 12. This Mendelian randomization study identified specific inflammatory cytokines associated with these tumors, providing direction for future mechanistic research.

17 days ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • TNFA (Tumor Necrosis Factor-Alpha) • CD5 (CD5 Molecule) • CSF1 (Colony stimulating factor 1) • CCL11 (C-C Motif Chemokine Ligand 11) • FGF21 (Fibroblast Growth Factor 21) • AXIN1 (Axin 1) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)

Causal effects of inflammatory cytokines on hemangioma mediated by blood metabolites: A two-step Mendelian randomization study. (PubMed, J Med Biochem)

As the first Mr study focused on hemangioma, we identified key cytokines and metabolites which might exert a causal effect on hemangioma, with several metabolites functioning as intermediators in cytokine-induced tumorigenesis process. The complex interaction between inflammation and metabolism in hemangioma was revealed, laying a foundation for future studies to explore potential targeted treatments.

1 month ago

Journal

CCL20 (C-C Motif Chemokine Ligand 20) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CCL11 (C-C Motif Chemokine Ligand 11) • IL17A (Interleukin 17A) • TGFA (Transforming Growth Factor Alpha)

2ms

CCL11 promotes hepatocellular carcinoma recurrence after surgery by potentiating immunosuppressive CCR5 + CD206 + M2-like macrophages and promoting tumor invasiveness. (PubMed, Cell Death Dis)

Our findings unveil CCL11 as a master regulator of the pro-tumorigenic niche post-resection, driving recurrence through coordinated immune evasion and promoting tumor invasiveness. Targeting the CCL11-CCR5/CCR3 axis presents a promising strategy to improve HCC surgical outcomes.

2 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule) • CCL11 (C-C Motif Chemokine Ligand 11) • MRC1 (Mannose Receptor C-Type 1) • CCR3 (C-C Motif Chemokine Receptor 3)

PD-L1 expression

2ms

Development and Internal Validation of a Pretransplant Biomarker Panel for Mortality Prediction Following Liver Transplant. (PubMed, JAMA Surg)

LIFI demonstrated strong discrimination (C statistic, 0.83) and was associated with post-LT infections, longer hospital stays, and reduced patient survival. Per the results of this diagnostic/prognostic study, LIFI identifies LT candidates with severe immune dysfunction at high risk for early post-LT mortality, offering a preoperative, objective tool to refine transplant candidacy, guide perioperative management, and improve LT outcomes.

2 months ago

Journal

CCL11 (C-C Motif Chemokine Ligand 11) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • IL1B (Interleukin 1, beta) • MMP3 (Matrix metallopeptidase 3)

2ms

Causal Relationships Between Plasma Metabolites, Inflammatory Factors, and Oral Cancer Risk: A Comprehensive Mendelian Randomization Study With Mediation Analysis. (PubMed, Hum Mutat)

Conversely, CCL11 overexpression promotes malignant cellular behavior, but these effects can be reversed by aspartate through inhibition of NF-κB and MAPK signaling pathways. This study elucidates a genetic variant-driven "metabolism-inflammation" carcinogenic pathway, providing novel insights into the mechanisms of oral cancer development and demonstrating significant translational potential for precision prevention and precision therapy.

2 months ago

Journal • Causal relationship

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CCL11 (C-C Motif Chemokine Ligand 11) • IL1B (Interleukin 1, beta)

2ms

A Comparative Toxicological Evaluation of Nicotine and Its Analog 6-Methyl Nicotine in E-Cigarette Aerosol Utilizing a 3D in vitro Human Respiratory Model. (PubMed, Toxicology)

Our findings reveal differential toxicological and chemical profiles for nicotine and 6-MN aerosols; however, flavorings may confer similar cytotoxicity, as measured by LDH and metabolic activity, in 6-MN formulations as they do in those with nicotine. Thus, 6-MN is not a "safer" nicotine alternative.

2 months ago

Preclinical • Journal

IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • CCL11 (C-C Motif Chemokine Ligand 11) • IL4 (Interleukin 4) • TP53BP1 (Tumor Protein P53 Binding Protein 1) • MUC5AC (Mucin 5AC) • OCLN (Occludin)

3ms

AP-CAT: Allergenic Extract Standardized Cat Hair AP in an Allergic Rhinitis Model. (clinicaltrials.gov)

P=N/A, N=20, Active, not recruiting, Queen's University | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2025 --> Jan 2026

3 months ago

Enrollment closed • Trial primary completion date

CCL11 (C-C Motif Chemokine Ligand 11) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • IL5 (Interleukin 5)

3ms

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study: Baseline Analysis of 24 Aqueous Cytokines. (PubMed, Ophthalmol Sci)

Our results lend support to the presumption that inflammatory cytokines are important biomarkers that associate with DR severity and may represent novel targets for inhibition. The authors have no proprietary or commercial interest in any materials discussed in this article.

3 months ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • FGF2 (Fibroblast Growth Factor 2) • CCL11 (C-C Motif Chemokine Ligand 11) • IL17A (Interleukin 17A) • CCL22 (C-C Motif Chemokine Ligand 22) • CD40LG (CD40 ligand) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4)

3ms

Multimodal biomarker landscape in vestibular schwannoma. (PubMed, Curr Opin Neurol)

This review outlines emerging circulating, tissue-derived and imaging biomarker candidates in VS that may complement MRI and support more precise diagnosis, monitoring, and individualized management.

3 months ago

Review • Journal

TNFRSF8 (TNF Receptor Superfamily Member 8) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • MIR155 (MicroRNA 155) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • MMP2 (Matrix metallopeptidase 2) • CCL11 (C-C Motif Chemokine Ligand 11) • MIR142 (MicroRNA 142) • MIR7 (MicroRNA 7) • CD80 (CD80 Molecule) • MMP14 (Matrix Metallopeptidase 14) • TGFBR1 (Transforming Growth Factor Beta Receptor 1) • S100B (S100 Calcium Binding Protein B)

4ms

EOFIB-SSC: Role of Eosinophil in Fibrogenesis of Systemic Sclerosis (clinicaltrials.gov)

P=N/A, N=70, Completed, University Hospital, Lille | Unknown status --> Completed

4 months ago

Trial completion

CCL11 (C-C Motif Chemokine Ligand 11)

4ms

Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer. (PubMed, Cancer Immunol Immunother)

Lenvatinib treatment has broad immunomodulatory effects in patients with TC, including shifts in immune cell populations, changes in the proteome, and reprogramming of cytokine responses. Lenvatinib also impacts monocyte metabolism and tumor cell phenotype. These findings provide insight into the multifaceted immunological activities of lenvatinib and highlight opportunities for treatment strategies.

4 months ago

Journal

IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL10 (Interleukin 10) • CCL11 (C-C Motif Chemokine Ligand 11) • CD40 (CD40 Molecule) • IL1B (Interleukin 1, beta) • IL1R1 (Interleukin 1 receptor, type I)

Lenvima (lenvatinib)